Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy

[1]  J. Reis-Filho,et al.  Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway , 2019, Molecular oncology.

[2]  O. Mariani,et al.  The Genomic Landscape of Mucinous Breast Cancer. , 2019, Journal of the National Cancer Institute.

[3]  J. Reis-Filho,et al.  Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. , 2019, JCO precision oncology.

[4]  J. Luke,et al.  WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers , 2019, Clinical Cancer Research.

[5]  R. Wolff,et al.  Power in pairs: assessing the statistical value of paired samples in tests for differential expression , 2018, BMC Genomics.

[6]  G. Tseng,et al.  Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles , 2018, Oncogene.

[7]  Martin L. Miller,et al.  Comprehensive Benchmarking and Integration of Tumour Microenvironment Cell Estimation Methods , 2018, bioRxiv.

[8]  Wyeth W. Wasserman,et al.  Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer , 2018, Cell.

[9]  Vladimir Vacic,et al.  Genome-wide somatic variant calling using localized colored de Bruijn graphs , 2018, Communications Biology.

[10]  A. Minn,et al.  Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. , 2018, Immunity.

[11]  C. Denkert,et al.  Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer , 2018, Neoplasia.

[12]  A. Whittemore,et al.  Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer , 2017, JAMA oncology.

[13]  G. Evan,et al.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression , 2017, Cell.

[14]  C. Zahnow,et al.  Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer , 2017, Cell.

[15]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[16]  Nikhil Wagle,et al.  Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.

[17]  C. Logsdon,et al.  The immune system in cancer metastasis: friend or foe? , 2017, Journal of Immunotherapy for Cancer.

[18]  Oliver Hofmann,et al.  Copy-number signatures and mutational processes in ovarian carcinoma , 2017, Nature Genetics.

[19]  Harini Veeraraghavan,et al.  Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.

[20]  Robert J. Lonigro,et al.  Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.

[21]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[22]  Ali Bashashati,et al.  Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.

[23]  Hannah C. Beird,et al.  Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma , 2017, npj Genomic Medicine.

[24]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[25]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[26]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[27]  The Gene Ontology Consortium,et al.  Expansion of the Gene Ontology knowledgebase and resources , 2016, Nucleic Acids Res..

[28]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[29]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[30]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[31]  G. Freeman,et al.  Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes , 2016, Cancer Immunology Research.

[32]  Naveena Singh,et al.  Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma , 2016, Clinical Cancer Research.

[33]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[34]  R. Kuick,et al.  Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer , 2016, Cell.

[35]  Ali Bashashati,et al.  Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer , 2016, Nature Genetics.

[36]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[37]  Robert Tibshirani,et al.  Post‐selection inference for ℓ1 ‐penalized likelihood models , 2016, The Canadian journal of statistics = Revue canadienne de statistique.

[38]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[39]  M. Vignali,et al.  T‐cell receptor profiling in cancer , 2015, Molecular oncology.

[40]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[41]  O. Mariani,et al.  Genomic landscape of adenoid cystic carcinoma of the breast , 2015, The Journal of pathology.

[42]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[43]  A. Weiss,et al.  Wnt ligand–dependent activation of the negative feedback regulator Nkd1 , 2015, Molecular biology of the cell.

[44]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[45]  Andrew Menzies,et al.  Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.

[46]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[47]  Erik Sahai,et al.  Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.

[48]  K. Manova-Todorova,et al.  Machine-based method for multiplex in situ molecular characterization of tissues by immunofluorescence detection , 2015, Scientific Reports.

[49]  Y. Kajiyama,et al.  PTCH1 mutation is a frequent event in oesophageal basaloid squamous cell carcinoma. , 2015, Mutagenesis.

[50]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[51]  J. Pollard,et al.  Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.

[52]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[53]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity , 2014, Journal of Immunotherapy for Cancer.

[54]  Sohrab P. Shah,et al.  TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data , 2014, Genome research.

[55]  M. Schatz,et al.  Accurate detection of de novo and transmitted indels within exome-capture data using micro-assembly , 2014, Nature Methods.

[56]  Michael C. Schatz,et al.  Accurate detection of de novo and transmitted INDELs within exome-capture data using micro-assembly , 2014, bioRxiv.

[57]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[58]  Dennis L. Sun,et al.  Exact post-selection inference, with application to the lasso , 2013, 1311.6238.

[59]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[60]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[61]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[62]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[63]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[64]  A. M. Rauwerdink,et al.  Ovarian cancer progression is controlled by phenotypic changes in dendritic cells , 2012, The Journal of experimental medicine.

[65]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[66]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[67]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[68]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[69]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[70]  C. Perou,et al.  Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.

[71]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[72]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[73]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[74]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[75]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[76]  Travis E. Oliphant,et al.  Python for Scientific Computing , 2007, Computing in Science & Engineering.

[77]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Yusuke Nakamura,et al.  DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway , 2004, Oncogene.

[79]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[80]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[81]  G. Mateu-Figueras,et al.  Isometric Logratio Transformations for Compositional Data Analysis , 2003 .

[82]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[83]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[84]  J L Pace,et al.  Development of a syngeneic mouse model for events related to ovarian cancer. , 2000, Carcinogenesis.

[85]  D. Sheskin.  Handbook of Parametric and Nonparametric Statistical Procedures: Third Edition , 2000 .

[86]  Teri A. Crosby,et al.  How to Detect and Handle Outliers , 1993 .

[87]  E. C. Pielou,et al.  Species-diversity and pattern-diversity in the study of ecological succession. , 1966, Journal of theoretical biology.

[88]  O. J. Dunn.  Multiple Comparisons among Means , 1961 .

[89]  M. Friedman.  The Use of Ranks to Avoid the Assumption of Normality Implicit in the Analysis of Variance , 1937 .

[90]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[91]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[92]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.